Lowenstein represented ZyVersa Therapeutics, Inc. (“ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory diseases with high unmet medical needs, in the closing its acquisition of Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company. ZyVersa will begin trading on Nasdaq on December 13, 2022 (Ticker ZVSA).
The business combination and related transactions were approved by Larkspur's stockholders at a special meeting on December 8, 2022. The combined company will operate as ZyVersa Therapeutics, Inc., under ZyVersa's previous management team.
In July, the combined company was estimated to have a pro forma enterprise valuation of approximately $108.92 million.
The Lowenstein deal team included Michael J. Lerner, Jared Kelly, Steven M. Skolnick, Kate Basmagian, Brian Silikovitz, Daniel C. Porco, James Assmann, Chelmie Ulysse, Ricardo Gray, Melissa D. Libutti, Lauren E. VanderDrift, and Barrett K. Davis.